Showing 97–108 of 116 results
-
Tivdak
FreeTrade Name Tivdak Active Ingredient Tisotumab Vedotin Power 40mg/ml Type / form Injection Status NA Manufacturer Roche -
Tracleer
FreeTrade Name Tracleer Active Ingredient Bosentan Power 62.5mg / 125mg Type / form Tablets Status NA Manufacturer Janssen -
Translarna
FreeTrade Name Translarna Active Ingredient Ataluren Power 125mg, 250mg,1000mg Type / form Sachets Status NA Manufacturer Ptc Therapeutics -
Tremfya
FreeTrade Name Tremfya Active Ingredient Guselkumab Power 100mg/ml Type / form Injection Status NA Manufacturer Janssen -
Trodelvy
FreeTrade Name Trodelvy Active Ingredient Sacituzuman Govitecan Power 200mg Type / form Injection Status NA Manufacturer Gilead -
Ultomiris
FreeMedicine Name: Ultomiris
Generic Name: RavulizumabDosage Form & Strength: Injection: 300 mg/30 mL (10 mg/mL) in a single-dose vial
Manufactured By: Alexion Pharmaceuticals, Inc. -
Uptravi
FreeTrade Name Uptravi Active Ingredient Selexipag Power 1800mcg Type / form Injection Status NA Manufacturer Janssen -
Vabysmo
FreeTrade Name Vabysmo Active Ingredient Ocrelizumab Power 300 mg Type / form Injection Status NA Manufacturer Roche -
Veletri
FreeTrade Name Veletri Active Ingredient Epoprostenol Power 0.5mg/ 1mg Type / form Injection Status NA Manufacturer Janssen -
Venclexta
FreeVenclexta is a BCL-2 inhibitor which contains Venetoclax. Venclexta uses are:
For treating chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), with or without 17p deletion, patients have received at least one therapy beforehand.
In combination with medication, azacitidine or decitabine, or low-dose cytarabine to treat newly-diagnosed acute myeloid leukemia (AML) in adult patients aged 75 years or older or with comorbidities that preclude the use of intensive induction chemotherapy.
Note: Venclexta is an FDA approved drug
-
-
Verzenio
FreeTrade Name Verzenio Active Ingredient Abemaciclib Power 150mg, 200mg Type / form Tablets Status NA Manufacturer Eli Lily
